An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients.
Interferon-beta is a biological treatment widely used in multiple sclerosis (MS). However, not every patient responds equally well to this therapy. In this study, our aim was to evaluate the influence of a dinucleotide microsatellite located in the first intron of the interferon-gamma gene on relapse eradication in a group of interferon-beta-treated patients. Our results show a very different allelic distribution when patients with relapses were compared with relapse-free patients.
Martínez
A
A
Clinical Immunology Department, Hospital Clinico San Carlos, C/ Martín Lagos s/n 28040 Madrid, Spain. alfmdoncel@terra.es
de las Heras
V
V
Mas Fontao
A
A
Bartolomé
M
M
de la Concha
E G
EG
Urcelay
E
E
Arroyo
R
R
D018900:Dinucleotide Repeats / Q000235:genetics*; D004351:Drug Resistance / Q000235:genetics*; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000235:genetics*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000235:genetics; D011110:Polymorphism, Genetic; D013030:Spain
D016899:Interferon-beta; D007371:Interferon-gamma